The expanded biomarker results also suggest that genomic tumour profiling will be needed to accurately identify the approximately 50% of patients whose tumours carry relevant PI3K/AKT/PTEN pathway alterations and will most benefit from capivasertib. This evidence concerns the gene PTEN and neoplasm.